Nastorazepide is a well-known 1,5-benzodiazepine derivative that acts as an antagonist ligand for CCK-2R, and it is currently under development as a therapeutic drug for pancreatic cancer, gastroesophageal reflux disease, and peptic ulcers. This evidence concerns the gene CCKBR and gastroesophageal reflux disease.